In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 141 to 150 of 434

TitleTypeExpected publication date
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6607]Technology appraisal guidanceTBC
Ensitrelvir for treating COVID 19 [ID6231]Technology appraisal guidanceTBC
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]Technology appraisal guidance
Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]Technology appraisal guidance
Epilepsies in children, young people and adultsNICE guidelineTBC
Epilepsies in children, young people and adults (extraordinary review)NICE guidelineTBC
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]Technology appraisal guidanceTBC
Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]Technology appraisal guidanceTBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920Technology appraisal guidanceTBC
Ex-situ machine perfusion devices for deceased donor liver transplantsHealth technology evaluation

Results per page

  1. 10
  2. 25
  3. 50
  4. All